Paradigm Biocapital Advisors LP
- SEC CIK
- 0001855655
- Latest filing
- Aug 14, 2026
Holdings in Q4 2022
Holdings as of Dec 31, 2022, filed Feb 14, 2023. Long positions only; changes compare share counts with Q3 2022.
- Positions
- 23
- −4 vs. Q3 2022
- Portfolio value
- $851.9M
- +$141.8M (+20.0%) vs. Q3 2022
| Security | Class | Shares | Value | % of portfolio | Share change | Action | History |
|---|---|---|---|---|---|---|---|
| INCYIncyte Corp | COM | 852,830 | $68.5M | 8.0% | +79,748+10.3% | Added | History |
| BIIBBiogen Inc. | COM | 238,772 | $66.1M | 7.8% | +84,167+54.4% | Added | History |
| MRTXMirati Therapeutics, Inc. | COM | 1,267,970 | $57.5M | 6.7% | +417,585+49.1% | Added | History |
| HZNPHorizon Therapeutics Public Ltd Co | SHS | 477,585 | $54.3M | 6.4% | +126,180+35.9% | Added | History |
| LEGNLegend Biotech Corp | SPONSORED ADS | 1,054,870 | $52.7M | 6.2% | −21,721−2.0% | Reduced | History |
| VRDNViridian Therapeutics, Inc. | COM | 1,751,167 | $51.2M | 6.0% | +114,956+7.0% | Added | History |
| SNDXSyndax Pharmaceuticals Inc | COM | 1,954,512 | $49.7M | 5.8% | +869,370+80.1% | Added | History |
| IMCRImmunocore Holdings plc | ADS | 857,925 | $49.0M | 5.7% | +84,846+11.0% | Added | History |
| ASNDAscendis Pharma A/S | SPONSORED ADR | 352,808 | $43.1M | 5.1% | −144,539−29.1% | Reduced | History |
| VORVor Biopharma Inc. | COM | 6,442,825 | $42.8M | 5.0% | +4,739,180+278.2% | Added | History |
| UTHRUnited Therapeutics Corp | COM | 148,892 | $41.4M | 4.9% | +8,331+5.9% | Added | History |
| SGENSeagen Inc. | COM | 286,288 | $36.8M | 4.3% | +286,288 | New | History |
| BCYCBicycle Therapeutics PLC | SPONSORED ADS | 1,233,280 | $36.5M | 4.3% | +74,594+6.4% | Added | History |
| ARGXArgenx SE | SPONSORED ADR | 89,556 | $33.9M | 4.0% | −741−0.8% | Reduced | History |
| AKROAkero Therapeutics, Inc. | COM | 604,544 | $33.1M | 3.9% | −228,721−27.4% | Reduced | History |
| ACLXArcellx, Inc. | COMMON STOCK | 882,101 | $27.3M | 3.2% | +882,101 | New | History |
| KRTXKaruna Therapeutics, Inc. | COM | 106,210 | $20.9M | 2.4% | +106,210 | New | History |
| ARVNArvinas, Inc. | COM | 599,599 | $20.5M | 2.4% | +315,822+111.3% | Added | History |
| ALPNAlpine Immune Sciences, Inc. | COM | 2,317,634 | $17.0M | 2.0% | +102,912+4.6% | Added | History |
| CRNXCrinetics Pharmaceuticals, Inc. | COM | 890,105 | $16.3M | 1.9% | +370,849+71.4% | Added | History |
| ZLABZai Lab Ltd | ADR | 515,274 | $15.8M | 1.9% | +515,274 | New | History |
| PSTXPoseida Therapeutics, Inc. | COM | 2,434,816 | $12.9M | 1.5% | +364,708+17.6% | Added | History |
| PRTAProthena Corp Public Ltd Co | SHS | 75,000 | $4.52M | 0.5% | −160,826−68.2% | Reduced | History |
Sold out since Q3 2022 (8)
Positions held at the end of Q3 2022 that are gone from this filing.
| Security | Class | Shares in Q3 2022 | Value in Q3 2022 | % of portfolio in Q3 2022 | History |
|---|---|---|---|---|---|
| GBTGlobal Blood Therapeutics, Inc. | COM | 1,175,879 | $80.1M | 11.3% | History |
| AXSMAxsome Therapeutics, Inc. | COM | 520,080 | $23.2M | 3.3% | History |
| ESPREsperion Therapeutics, Inc. | COM | 1,719,831 | $11.5M | 1.6% | History |
| MRUSMerus N.V. | COM | 564,214 | $11.3M | 1.6% | History |
| GTHXG1 Therapeutics, Inc. | COM | 884,574 | $11.0M | 1.6% | History |
| OYSTOyster Point Pharma, Inc. | COM | 1,648,316 | $9.26M | 1.3% | History |
| TGTXTG Therapeutics, Inc. | COM | 1,505,479 | $8.91M | 1.3% | History |
| MISTMilestone Pharmaceuticals Inc. | COM | 634,211 | $5.83M | 0.8% | History |